The name of the treatment contains in a single word a connection with urologic application (“Soracte” is the name of an Italian mountain (also named in the incipit of an Horace Poem), where there was a monastery in which the monk Nonnoso, canonized, is considered the protector of people with kidney disease) and “Lite”, which on one hand refers to the lightweight and micro-invasiveness of the treatment, and on the other, the therapeutic source (Light, therefore Laser).
The name SORACTELite® allows for differentiating the procedure with ECHOLASER® (micro-invasiveness and multi-fibre approach in a single system) from the other thermal ablation techniques
When SORACTELite® is used?
SORACTELite® is indicated in the case of patients suffering from Benign Prostatic Hyperplasia, a disease in which the volumetric increase in the prostate gland generates a compression effect at the level of the bladder floor and the urethral canal, and also in the case of subjects who choose not to undergo surgical treatment.
When you hear the word laser in urology, you instantly may think of surgical lasers, like the green laser. These lasers are an important advancement for endoscopic, transurethral surgery of the prostate. However, SORACTELite® has got nothing to do with surgical lasers; in fact, it differs in:
wavelength and power (our laser is not visible as opposed to green),
- its mode of action (cytoreduction vs surgical vaporization), and lastly and most importantly
- SORACTELite® is performed in a truly microinvasive approach (transperineal vs transurethral).
SORACTELite® represents true innovation for BPH treatment
Despite focusing mainly on the treatment of Benign Prostatic Hyperplasia (BPH), SORACTELite® is also effective for prostate cancer that is not clinically relevant combined with active surveillance and post-prostatectomy relapse and for kidney cancer.
SORACTELite® treatment consists of the percutaneous insertion of optical fibres (one or two fibres per lobe depending on the basal volume of the prostatic gland) via transperineal access, and the delivery of laser energy for several minutes which causes the heating of the tissues until they are destroyed, followed by a progressive reduction in the volume of the prostatic lobe (a reduction of at least 40% compared to the basal volume at the one-year follow-up) and subsequent disappearance of the symptoms. The planning of the treatment, the insertion of the needles and the monitoring are all carried out under ultrasound guidance. In order to facilitate the insertion manoeuvre, the system has a dedicated multi-applicator Guiding System for transrectal ultrasound probe with relative Biopsy Software that displays the guidelines on the screen.
- resolution of symptoms
- “in situ” thermal damage with consequent reduction of the prostatic lobe
- preservation of the healthy tissue and the organ function
- highly predictable and repeatable coagulation volume
- use of fine, a-traumatic needles with transperineal approach
- absence of general anaesthesia
- short duration of the treatment (few minutes)
- rapid recovery times
- no or insignificant post-treatment pain
- absence of erectile dysfunction or complications linked to the reproductive organs